ADPT
Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp
$ADPT Reports Impressive Revenue Growth and Promising Developments in MRD and Immune Medicine for Q1 2023
Adaptive Biotechnologies posted total revenue of $101.5mn for Q1 2023, driven by impressive MRD growth and a partnership with Takeda. The company's CEO reinforced its commitment to immuno-medicine while maximizing operational efficiencies for growth. Consolidation of key roles and a commitment to improving performance was highlighted. However, investors should remain cautious of uncertainties in the market while admiring the strong financial growth of Adaptive Biotechnologies.
4mo ago
$ADPT